Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (12953)	9/29/2003 7:01:48 PM
From: DaveAu	Respond to of 14101

Nice find Joe. I've definitely seen articles by this fellow before - I think in the Toronto Sun which is not a paper I normally read (except the sunshine girl). Dave

To: Joe Krupa who wrote (12953)	9/30/2003 12:43:21 AM
From: axial	Read Replies (1) \| Respond to of 14101

Hi, Joe - Good stuff. Thanks for posting the article. We're beginning to find out that Canadian physicians like Pennsaid. A lot. Pennsaid: A - The rationale for its use make sense B - "It works, and works well" ®CG After all the waiting, the negativity, the disappointments and stalling from HC, Pennsaid sales numbers come like cool water to thirsty DMX travellers. I've been conducting my own informal poll out here. What a difference a few months makes! Every pharmacy I've been to in this area now has recurring Pennsaid sales. I've learned of people who were put on Pennsaid by their physicians as soon as it hit the market - and haven't stopped using it. Early days yet, but it sure looks like this product has legs. Conceivably, we may hit 3% market share - or better - in this fiscal year. Hard to believe the product has only been selling for 6 months. As Wolf has pointed out, once we get past 3%, DMX starts to look a lot better. So does the whole question of the the US distributor - and the upfront to Dimethaid. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ This is just speculation on my part, but how about a combined Pennsaid/WF10 deal with JnJ? Jim ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ "Hepatitis C is a blood-borne infectious disease of the liver that affects millions of people worldwide, and is the leading cause of cirrhosis and liver cancer," said David Ciavarella, M.D., Executive Director, Clinical and Medical Affairs, Ortho-Clinical Diagnostics. "It is also the number-one reason for liver transplants in the United States." "On an average it takes about 10 to 20 years for serious symptoms such as jaundice, fatigue, dark urine, abdominal pain, loss of appetite and nausea to occur," Ciavarella added. "At this point, when patients learn their livers are failing, their only hope is often a liver transplant. But now early detection and treatment is possible through increased public awareness and primary care physician utilization of anti-HCV tests." Among those at greatest risk for hepatitis C: Hemophiliacs, intravenous drug users, current or past dialysis patients, transfusion-transplant patients, healthcare workers and those engaging in high-risk sexual activities. The CDC estimates that hepatitis C is responsible for eight to ten thousand deaths per year and that this amount could increase substantially during the next ten years. Source: Ortho-Clinical Diagnostics; Johnson & Johnson, Sept. 28, 2001

To: Joe Krupa who wrote (12953)	9/30/2003 7:26:41 PM
From: gg cox	Read Replies (1) \| Respond to of 14101

Page 10 of October issue of 50 Plus magazine here.. 50plus.com "Topical treatment for osteoarthritis gets the nod For Canadians suffering with osteoarthritis of the knee, a new weapon has been developed in the fight against the daily aches, pains, stiffness and sometimes debilitating effects associated with the disease. Pensaid is a topical non-steroidal anti-inflammatory drug (NSAID) recently approved by Health Canada, developed as an alternative to oral NSAIDs for treatment of osteoarthritis of the knee. Pennsaid eliminates the risk of the side effects associated with oral NSAIDs, such as gastrointestinal bleeding, and kidney and liver disease. The new topically applied treatment may be just the drug OA sufferes have been waiting for. Pennsaid works by delivering diclofenac sodium, an anti-arthritic, through the skin directly to the site of pain. Side effects of Pennsaid can include dry or irritated skin. Ask your doctor if Pennsaid is a good choice for you." Should give sales a nice boost. gg